LataMed AI Corp. (OTC: LMED) announced today that its mobile healthcare application has entered the final stage of development, with the company completing testing, optimization, and deployment preparation ahead of planned availability through the Apple App Store and Google Play. Management expects the application to be submitted for distribution and, subject to applicable platform review and technical requirements, become available in the coming weeks.
This milestone signifies a transition from application development to public availability, providing users with a convenient mobile interface to access the LataMed AI digital healthcare ecosystem. The app is designed to be a primary access point, offering supported healthcare services, digital tools, and additional functionality as the platform expands.
The development team is focused on final technical testing, interface optimization, platform compatibility review, and other deployment-related preparations. Once launched, the app is expected to provide a scalable mobile foundation for introducing future features, including patient-facing tools, healthcare-provider interaction, digital communications, medical and wellness information, and healthcare-service coordination.
Mobile accessibility is particularly crucial in Latin America, where smartphones are a primary means of accessing digital services. By launching on both major app stores, LataMed AI aims to offer users a direct and accessible way to engage with its developing healthcare ecosystem, while establishing infrastructure for future growth.
The app also supports the company's long-term strategy of connecting patients, healthcare professionals, pharmacies, insurers, payment providers, wellness organizations, and other stakeholders in a more integrated digital healthcare environment. LataMed AI continues to develop its AI-supported technologies, including CardioAI, PulmoAI, and NeuroAI, as part of its broader strategy. The mobile infrastructure will ultimately provide an additional pathway for users and healthcare professionals to interact with the ecosystem, subject to continued development and regulatory requirements.
Dr. Kevin Rodan Levy, CEO of LataMed AI, stated, "Our mobile application is now moving from development toward deployment, and we believe we are approaching an important milestone for LataMed AI. Our team is completing the final stages of testing and preparation, and we currently expect the application to become available through the Apple App Store and Google Play in the coming weeks, subject to the applicable platform review processes." He added, "Mobile availability is important because it provides a direct connection between users and the digital healthcare ecosystem we are building. Our objective is to create a platform that is practical, accessible, and capable of expanding as we continue introducing additional healthcare services and artificial intelligence-supported tools."
The anticipated release represents a step in moving LataMed AI's technology from development to user-facing infrastructure. Following the initial launch, the company intends to evaluate additional functionality, platform integrations, and user-facing tools for future versions. Updates on submission and availability will be provided as milestones are completed.
For more information, visit https://latamed.ai or review the company's SEC filings at www.sec.gov.
